Dupilumab for Moderate-to-Severe Atopic Dermatitis Dupilumab for Moderate-to-Severe Atopic Dermatitis

Dupilumab, an IL-4 and IL-13 antagonist, was recently FDA approved for patients with moderate-to-severe atopic dermatitis. Will it be a game-changer in the management of this challenging condition?Skin Therapy Letter
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news